ArticleBMC bioinformatics2026
Machine learning framework for cost effective deep mutational scanning through targeted substitution profiling.
Article in BMC bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundDeep mutational scanning (DMS) provides comprehensive maps of protein variant effects but remains experimentally intensive. Machine learning (ML) approaches have the potential to reduce experimental burden of DMS by predicting the functional impact of substitutions from limited data.
resultsWe introduced a ML classifier trained on normalised DMS scores from SARS-CoV-2 main protease (Mpro) to categorise amino acid substitutions as functional (wild-type-like) or non-functional. Using brute-force feature selection, we identified minimal subsets of six substitution scores per residue that enable accurate classification of the remaining substitutions, achieving minimum (worst accuracy) scores exceeding 90%. Models including support vector machines, random forests, and logistic regression were evaluated without retraining (zero-shot prediction) against additional SARS-CoV-2 Mpro datasets and against unrelated datasets. The zero-shot performance of the models was strongest for other enzymes and more modest when applied to DMS systems that assess protein folding and/or protein-protein interactions.
conclusionThe results show that targeted DMS combined with ML can reduce sequencing and reagent costs while preserving classification accuracy, offering a practical route to accelerate variant effect prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.